Integration of metabolomics, lipidomics and clinical data using a machine learning method

Abstract Background The recent pandemic of obesity and the metabolic syndrome (MetS) has led to the realisation that new drug targets are needed to either reduce obesity or the subsequent pathophysiological consequences associated with excess weight gain. Certain nuclear hormone receptors (NRs) play...

Full description

Bibliographic Details
Main Authors: Animesh Acharjee, Zsuzsanna Ament, James A. West, Elizabeth Stanley, Julian L. Griffin
Format: Article
Language:English
Published: BMC 2016-11-01
Series:BMC Bioinformatics
Online Access:http://link.springer.com/article/10.1186/s12859-016-1292-2
id doaj-76b05c5a13d842118f92839eb0e9f75a
record_format Article
spelling doaj-76b05c5a13d842118f92839eb0e9f75a2020-11-25T00:15:13ZengBMCBMC Bioinformatics1471-21052016-11-0117S15374910.1186/s12859-016-1292-2Integration of metabolomics, lipidomics and clinical data using a machine learning methodAnimesh Acharjee0Zsuzsanna Ament1James A. West2Elizabeth Stanley3Julian L. Griffin4Medical Research Council, Elsie Widdowson LaboratoryMedical Research Council, Elsie Widdowson LaboratoryMedical Research Council, Elsie Widdowson LaboratoryMedical Research Council, Elsie Widdowson LaboratoryMedical Research Council, Elsie Widdowson LaboratoryAbstract Background The recent pandemic of obesity and the metabolic syndrome (MetS) has led to the realisation that new drug targets are needed to either reduce obesity or the subsequent pathophysiological consequences associated with excess weight gain. Certain nuclear hormone receptors (NRs) play a pivotal role in lipid and carbohydrate metabolism and have been highlighted as potential treatments for obesity. This realisation started a search for NR agonists in order to understand and successfully treat MetS and associated conditions such as insulin resistance, dyslipidaemia, hypertension, hypertriglyceridemia, obesity and cardiovascular disease. The most studied NRs for treating metabolic diseases are the peroxisome proliferator-activated receptors (PPARs), PPAR-α, PPAR-γ, and PPAR-δ. However, prolonged PPAR treatment in animal models has led to adverse side effects including increased risk of a number of cancers, but how these receptors change metabolism long term in terms of pathology, despite many beneficial effects shorter term, is not fully understood. In the current study, changes in male Sprague Dawley rat liver caused by dietary treatment with a PPAR-pan (PPAR-α, −γ, and –δ) agonist were profiled by classical toxicology (clinical chemistry) and high throughput metabolomics and lipidomics approaches using mass spectrometry. Results In order to integrate an extensive set of nine different multivariate metabolic and lipidomics datasets with classical toxicological parameters we developed a hypotheses free, data driven machine learning approach. From the data analysis, we examined how the nine datasets were able to model dose and clinical chemistry results, with the different datasets having very different information content. Conclusions We found lipidomics (Direct Infusion-Mass Spectrometry) data the most predictive for different dose responses. In addition, associations with the metabolic and lipidomic data with aspartate amino transaminase (AST), a hepatic leakage enzyme to assess organ damage, and albumin, indicative of altered liver synthetic function, were established. Furthermore, by establishing correlations and network connections between eicosanoids, phospholipids and triacylglycerols, we provide evidence that these lipids function as a key link between inflammatory processes and intermediary metabolism.http://link.springer.com/article/10.1186/s12859-016-1292-2
collection DOAJ
language English
format Article
sources DOAJ
author Animesh Acharjee
Zsuzsanna Ament
James A. West
Elizabeth Stanley
Julian L. Griffin
spellingShingle Animesh Acharjee
Zsuzsanna Ament
James A. West
Elizabeth Stanley
Julian L. Griffin
Integration of metabolomics, lipidomics and clinical data using a machine learning method
BMC Bioinformatics
author_facet Animesh Acharjee
Zsuzsanna Ament
James A. West
Elizabeth Stanley
Julian L. Griffin
author_sort Animesh Acharjee
title Integration of metabolomics, lipidomics and clinical data using a machine learning method
title_short Integration of metabolomics, lipidomics and clinical data using a machine learning method
title_full Integration of metabolomics, lipidomics and clinical data using a machine learning method
title_fullStr Integration of metabolomics, lipidomics and clinical data using a machine learning method
title_full_unstemmed Integration of metabolomics, lipidomics and clinical data using a machine learning method
title_sort integration of metabolomics, lipidomics and clinical data using a machine learning method
publisher BMC
series BMC Bioinformatics
issn 1471-2105
publishDate 2016-11-01
description Abstract Background The recent pandemic of obesity and the metabolic syndrome (MetS) has led to the realisation that new drug targets are needed to either reduce obesity or the subsequent pathophysiological consequences associated with excess weight gain. Certain nuclear hormone receptors (NRs) play a pivotal role in lipid and carbohydrate metabolism and have been highlighted as potential treatments for obesity. This realisation started a search for NR agonists in order to understand and successfully treat MetS and associated conditions such as insulin resistance, dyslipidaemia, hypertension, hypertriglyceridemia, obesity and cardiovascular disease. The most studied NRs for treating metabolic diseases are the peroxisome proliferator-activated receptors (PPARs), PPAR-α, PPAR-γ, and PPAR-δ. However, prolonged PPAR treatment in animal models has led to adverse side effects including increased risk of a number of cancers, but how these receptors change metabolism long term in terms of pathology, despite many beneficial effects shorter term, is not fully understood. In the current study, changes in male Sprague Dawley rat liver caused by dietary treatment with a PPAR-pan (PPAR-α, −γ, and –δ) agonist were profiled by classical toxicology (clinical chemistry) and high throughput metabolomics and lipidomics approaches using mass spectrometry. Results In order to integrate an extensive set of nine different multivariate metabolic and lipidomics datasets with classical toxicological parameters we developed a hypotheses free, data driven machine learning approach. From the data analysis, we examined how the nine datasets were able to model dose and clinical chemistry results, with the different datasets having very different information content. Conclusions We found lipidomics (Direct Infusion-Mass Spectrometry) data the most predictive for different dose responses. In addition, associations with the metabolic and lipidomic data with aspartate amino transaminase (AST), a hepatic leakage enzyme to assess organ damage, and albumin, indicative of altered liver synthetic function, were established. Furthermore, by establishing correlations and network connections between eicosanoids, phospholipids and triacylglycerols, we provide evidence that these lipids function as a key link between inflammatory processes and intermediary metabolism.
url http://link.springer.com/article/10.1186/s12859-016-1292-2
work_keys_str_mv AT animeshacharjee integrationofmetabolomicslipidomicsandclinicaldatausingamachinelearningmethod
AT zsuzsannaament integrationofmetabolomicslipidomicsandclinicaldatausingamachinelearningmethod
AT jamesawest integrationofmetabolomicslipidomicsandclinicaldatausingamachinelearningmethod
AT elizabethstanley integrationofmetabolomicslipidomicsandclinicaldatausingamachinelearningmethod
AT julianlgriffin integrationofmetabolomicslipidomicsandclinicaldatausingamachinelearningmethod
_version_ 1725388049095852032